Insmed Incorporated research snapshot
INSM AI stock analysis sees Insmed as a commercial-stage rare-disease company with an exceptional BRINSUPRI launch, a growing ARIKAYCE franchise, and late-stage TPIP optionality, but the market is questioning patient persistence on BRINSUPRI and the breadth of the pipeline. At the August 2, 2026 cutoff, INSM traded near $98.60 with a verified market capitalization of $21.37 billion, roughly 54% below its 52-week high of $212.75 and close to the 52-week low of $90.39. Sales growth and guidance remain strong, but the company is still loss-making, uses about $900 million of cash a year, carries debt and royalty obligations, and depends on sustained persistence, reimbursement, regulatory execution, clinical data, and financing discipline. This page is informational only and not investment advice.
Current price
$98.60
Market cap
$21.37 billion
AI score
55 / 100
Rating
Strong commercial execution but elevated persistence and pipeline risk, with the stock near a 52-week low
Trend status
Below the 50-day and 200-day moving averages, near the 52-week low of $90.39
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Insmed sells specialty respiratory therapies for underserved patient groups. BRINSUPRI and ARIKAYCE create recurring treatment revenue, but demand depends on diagnosis, access, prescriber adoption, patient persistence, and adherence. | Medium-high |
| Moat | Regulatory approvals, orphan-disease expertise, physician relationships, clinical data, and manufacturing know-how create barriers. The moat is product-specific, and the BRINSUPRI expansion setbacks in hidradenitis suppurativa and chronic rhinosinusitis show it does not automatically transfer to new indications. | Medium |
| Management | Chair and CEO Will Lewis has led an industry-leading BRINSUPRI launch and a growing pipeline. The key test is whether strong commercial execution converts into durable persistence and a credible path to cash flow positivity in 2027 without dilutive financing. | Medium |
| Financial trend | FY2025 revenue was $606.4 million, up 66.7%, and Q1 2026 revenue was $306.0 million, up about 230% year over year, led by BRINSUPRI at $207.9 million. The company still reported a $163.6 million net loss in Q1 2026, and TTM free cash flow was about negative $922 million. | High |
| Valuation | At $98.60, INSM had a $21.37 billion market cap, negative TTM earnings and free cash flow, a PS ratio near 26x on trailing revenue, and about 11x forward PS on the roughly $1.7 billion 2026 consensus revenue estimate. Conventional P/E and P/FCF provide no margin-of-safety signal. | High |
| Technical trend | INSM closed at $98.60 on July 31, 2026, below its 50-day moving average near $104.88 and its 200-day average near $147.61. RSI near 34 reflected weak momentum close to oversold, and the stock is within about 9% of the 52-week low of $90.39. | Medium-high |
| Risk level | Risk is high. Persistence and discontinuation rates, reimbursement, commercialization, supply, regulatory decisions, clinical trial outcomes, cash burn, debt and royalty financing, dilution, index-flow effects, and competition can all materially change value. | High |
| AI confidence | Reported financial, price, and technical data are well documented, but AI cannot know future persistence behavior, payer decisions, patient identification, clinical outcomes, financing, or market sentiment. | High data confidence |
| Investment certainty | Investment certainty is lower than data confidence because a large portion of the valuation depends on revenue that has not yet been earned, on persistence that is under active debate, and on clinical programs that have not yet read out. | Low-medium |
INSM AI stock forecast
The INSM AI stock forecast uses scenarios instead of a promised price. The auditable three-year model applies illustrative normalized EPS of $1.50, growth rates of 40%, 25%, and 10%, and terminal P/E multiples of 45x, 30x, and 18x, giving targets near $185, $88, and $36. These are valuation assumptions, not company guidance, because INSM currently reports a net loss. The sell-side consensus sits higher, with a Strong Buy rating and an average price target near $196 per S&P Global as of July 28, 2026.
$170 to $190
More likely if BRINSUPRI exceeds the at-least-$1 billion 2026 revenue guide while persistence stays healthy, international access expands, ARIKAYCE label expansion progresses, TPIP Phase 3 data support a large opportunity, and cash flow positivity in 2027 looks achievable without dilution.
$85 to $105
More likely if BRINSUPRI and ARIKAYCE broadly meet guidance but persistence debates persist, commercial spending and pipeline investment delay profitability, and the market keeps applying a lower multiple to longer-dated earnings.
$30 to $45
More likely if persistence and discontinuation rates disappoint, payer access or diagnosis expansion stalls, key studies or regulatory events weaken the pipeline, cash burn stays high, or financing needs force further dilution before earnings scale.
INSM AI technical analysis
INSM AI technical analysis uses the August 2, 2026 StockAnalysis market snapshot. The static page does not fetch live market data. The $98.60 reference was below both the 50-day and 200-day moving averages, so the longer-term trend is down and the stock is near the lower end of its 52-week range after the June 2026 selloff.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $98.60 | Close on July 31, 2026, down 2.85% on the day, used for the analysis and market-cap calculation. |
| Near support | $95 to $97 | Recent July lows cluster near $95 to $99. A live chart should confirm whether this area attracts demand. |
| Secondary support | $90 to $92 | The 52-week low was $90.39 on June 10, 2026. It is a monitoring level, not a guaranteed floor. |
| Near resistance | $104.88 | The 50-day moving average sits near $104.88. A sustained move above it would improve the short-term trend case. |
| Long-term resistance | $147.61 | The 200-day moving average was $147.61. A sustained move above it would be needed to repair the long-term trend. |
| Momentum | RSI 34.14 | Momentum was weak and near oversold. RSI below 30 would signal oversold conditions, but a low RSI alone is not a buy signal. |
| Volume | 2.33 million average shares | StockAnalysis reported 20-day average volume of 2,329,013 shares. Breakouts need confirming volume, and index-flow moves around the Nasdaq-100 removal were heavy in June. |
| Volatility | Beta 0.78, event-driven | Reported beta was below one, but drug, earnings, regulatory, financing, and index events can still produce sharp gaps. |
| Short interest | 5.36% of shares outstanding | Short interest of about 11.62 million shares is lower than a month earlier, but short positioning can still add volatility around news. |
| Invalidation | Sustained close below $90 | A sustained close below the 52-week low of $90.39 would extend the downtrend and should trigger a full review of price action and fundamentals. |
INSM AI trading strategy
The INSM AI trading strategy is a research and risk-control framework, not a personalized recommendation. It combines live chart confirmation with quarterly revenue, persistence and discontinuation data, payer access, patient starts, cash use, financing, regulatory dates, and clinical milestones, including the Q2 2026 earnings report scheduled for August 6, 2026.
Monitor whether INSM reclaims the 50-day moving average near $104.88 and later the 200-day average near $147.61 with volume. Confirm the price action with new evidence on BRINSUPRI persistence and no deterioration in guidance or cash.
A sustained close below about $90 extends the downtrend. Size exposure for biotechnology event gaps rather than relying on a tight stop alone.
If INSM approaches the 52-week low near $90 without a negative persistence, product, payer, regulatory, or trial update, compare the price change with the next revenue report, persistence data, and cash-use trend before acting.
Do not assume a support level will hold when the underlying news changes. Missed guidance, a negative persistence update, or an adverse clinical event can make a technical bounce fail.
Track BRINSUPRI sales against the at-least-$1 billion guide, ARIKAYCE guidance, persistence and discontinuation disclosures, cash and marketable securities, operating cash use, term-loan and royalty obligations, ENCORE label progress, TPIP Phase 3 trials, and new financing.
Reduce confidence if persistence weakens while operating cash use stays high, if access or adherence disappoints, if pipeline timelines extend without stronger evidence, or if the company needs to raise dilutive capital before profitability.
Investment research summary
Insmed develops and commercializes therapies for serious, underserved respiratory diseases. Customers and payers pay when products show clinical value, gain coverage, keep patients on therapy, and are manufactured and supplied reliably.
The moat comes from orphan and respiratory disease expertise, approval history, clinical evidence, prescriber education, specialty distribution, and manufacturing. It can narrow if competing therapies offer better efficacy, safety, convenience, persistence, or price, and the discontinued BRINSUPRI programs show it does not transfer automatically to every indication.
The thesis fails if BRINSUPRI persistence or discontinuation rates disappoint, payer access or diagnosis expansion is slower than expected, ARIKAYCE demand weakens, clinical programs disappoint, safety or supply issues emerge, or cash needs force further dilutive financing.
Management has built Insmed into a two-product commercial company while advancing a wider pipeline, and it guided toward cash flow positivity in 2027. The next capital-allocation test is whether commercial and R&D spending translate into durable operating leverage and strong persistence before liquidity becomes a concern.
Rare respiratory and inflammatory disease treatment benefits from better diagnosis, targeted therapy, and specialist care. The opportunity is meaningful, but markets can be constrained by payer rules, patient finding, persistence, competition, and trial execution.
The market is valuing expected future BRINSUPRI, ARIKAYCE, and TPIP cash flows rather than present earnings. The drawdown has reduced the entry price, but margin of safety is still limited until persistence durability, cash burn improvement, and a path to profitability become clearer.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| INSM price | $98.60 | StockAnalysis quote snapshot | August 2, 2026 |
| Market capitalization | $21.37 billion, verified as $98.60 x 216.75 million shares | financial_rigor.py and StockAnalysis | August 2, 2026 |
| 52-week range | $90.39 to $212.75 | StockAnalysis statistics and price history | August 2, 2026 |
| FY2025 revenue | $606.42 million, up 66.73% year over year | Insmed 2025 annual report and StockAnalysis cross-check | August 2, 2026 |
| Q1 2026 revenue | $306.0 million, including $207.9 million BRINSUPRI and $98.1 million ARIKAYCE | Insmed Q1 2026 financial results and StockAnalysis cross-check | August 2, 2026 |
| Q1 2026 net loss | $163.6 million, or $0.76 per share, versus $256.6 million a year earlier | Insmed Q1 2026 financial results | August 2, 2026 |
| Cash and marketable securities | About $1.2 billion at March 31, 2026 | Insmed Q1 release and StockAnalysis cross-check | August 2, 2026 |
| Debt | $742.46 million total debt; $481.05 million net cash at March 31, 2026 | StockAnalysis balance sheet and SEC Form 10-Q | August 2, 2026 |
| TTM free cash flow | About negative $921.64 million through Q1 2026 | StockAnalysis cash flow statement | August 2, 2026 |
| Valuation math | PS about 26x trailing revenue and about 11x forward consensus revenue; P/E and P/FCF not meaningful with negative TTM EPS and free cash flow; PB about 30x | financial_rigor.py valuation verification | August 2, 2026 |
| Analyst consensus | Strong Buy with an average price target near $196.18 from 23 analysts | StockAnalysis and S&P Global Market Intelligence | July 28, 2026 |
| Technical inputs | 50-day MA $104.88, 200-day MA $147.61, RSI 34.14, 20-day average volume 2.33 million | StockAnalysis statistics | August 2, 2026 |
| TPIP 12-month OLE data | Sustained improvement in 6MWD, NT-proBNP, WHO Functional Class, and REVEAL Lite 2.0 with no newly identified safety signals | Insmed press release, July 16, 2026 | August 2, 2026 |
This INSM AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available public filings, quote snapshots, technical data, and third-party sources as of August 2, 2026. They may be wrong, incomplete, or outdated after new earnings, product sales, persistence updates, payer updates, clinical data, regulatory decisions, financing, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
